Scarica l'app Stockscreener
4.89
1.24%
0.06
Dopo l'orario di chiusura:
4.88
-0.010
-0.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
Will Recursion Pharmaceuticals Inc. stock recover after recent dropRate Hike & Free Community Supported Trade Ideas - Newser
Recursion Pharmaceuticals Inc. stock prediction for this weekJobs Report & Weekly High Potential Stock Alerts - Newser
Tools to assess Recursion Pharmaceuticals Inc.’s risk profileStock Surge & Breakout Confirmation Trade Signals - Newser
Quantitative breakdown of Recursion Pharmaceuticals Inc. recent moveWeekly Gains Report & Fast Exit Strategy with Risk Control - Newser
Multi factor analysis applied to Recursion Pharmaceuticals Inc.Trade Ideas & Expert Curated Trade Ideas - Newser
Market reaction to Recursion Pharmaceuticals Inc.’s recent newsGap Down & Weekly Market Pulse Updates - Newser
Will Recursion Pharmaceuticals Inc. continue its uptrendJuly 2025 Sector Moves & Daily Volume Surge Signals - Newser
Is it too late to sell Recursion Pharmaceuticals Inc.July 2025 Weekly Recap & Fast Entry and Exit Trade Plans - Newser
Is Recursion Pharmaceuticals Inc. building a consolidation base2025 Key Lessons & Free Reliable Trade Execution Plans - Newser
Real time breakdown of Recursion Pharmaceuticals Inc. stock performance2025 Macro Impact & Technical Confirmation Alerts - Newser
Understanding Recursion Pharmaceuticals Inc.’s price movement2025 Market Outlook & AI Forecast Swing Trade Picks - Newser
Applying chart zones and confluence areas to Recursion Pharmaceuticals Inc.Market Growth Summary & Stock Portfolio Risk Control - Newser
Recursion's Strategic Conference Participation and AI-Driven Drug Discovery Model - AInvest
Recursion to Participate in Upcoming Investor Conferences - MarketScreener
Historical volatility pattern of Recursion Pharmaceuticals Inc. visualized2025 Market Trends & Growth Focused Stock Pick Reports - Newser
Sector ETF performance correlation with Recursion Pharmaceuticals Inc.Weekly Trade Summary & Accurate Entry and Exit Point Alerts - Newser
Building trade automation scripts for Recursion Pharmaceuticals Inc.Insider Selling & Free Expert Verified Stock Movement Alerts - Newser
Backtesting results for Recursion Pharmaceuticals Inc. trading strategiesJuly 2025 Sentiment & Fast Momentum Entry Tips - Newser
Visual analytics tools that track Recursion Pharmaceuticals Inc. performanceEarnings Risk Report & Weekly Top Stock Performers List - Newser
Visualizing Recursion Pharmaceuticals Inc. stock with heatmapsTrade Analysis Report & Risk Managed Investment Signals - Newser
Full technical analysis of Recursion Pharmaceuticals Inc. stockMarket Growth Report & Technical Entry and Exit Alerts - Newser
Earnings visualization tools for Recursion Pharmaceuticals Inc.2025 EndofYear Setup & Accurate Entry and Exit Point Alerts - Newser
Nvidia CEO Jensen Huang Was Dubbed 'Godfather of AI.' The Company Is Betting On These AI Stocks - Investopedia
Recursion Pharmaceuticals Inc. Chart Enters High Volatility Zone getLinesFromResByArray error: size == 0 - kangso.co.kr
Will Recursion Pharmaceuticals Inc. benefit from macro trendsJuly 2025 Institutional & Real-Time Chart Pattern Alerts - Newser
Measuring Recursion Pharmaceuticals Inc.’s beta against major indicesJuly 2025 PreEarnings & Risk Controlled Daily Trade Plans - Newser
Ranking Recursion Pharmaceuticals Inc. among high performing stocks via toolsCEO Change & Long-Term Capital Growth Strategies - Newser
Does Recursion Pharmaceuticals Inc. qualify in momentum factor screeningTrade Volume Report & Short-Term Trading Opportunity Alerts - Newser
What’s the recovery path for long term holders of Recursion Pharmaceuticals Inc.Quarterly Investment Review & Low Risk Investment Opportunities - Newser
Can Recursion Pharmaceuticals Inc. hit a new high this monthJuly 2025 Price Swings & Reliable Price Breakout Signals - Newser
1 Reason to Buy This Beaten-Down Artificial Intelligence (AI) Stock, and 2 Reasons to Sell - Yahoo Finance
Needham Maintains Buy Rating on Recursion (RXRX) - MSN
Recursion Pharmaceuticals Inc. stock outlook for YEARWeekly Market Summary & Target Return Focused Stock Picks - Newser
Live market analysis of Recursion Pharmaceuticals Inc.2025 Market Trends & Scalable Portfolio Growth Methods - Newser
Recursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of Shares - MSN
Recursion Pharmaceuticals (RXRX): A High-Risk, High-Reward Play in the AI-Driven Drug Discovery Revolution - AInvest
Real time pattern detection on Recursion Pharmaceuticals Inc. stockPrice Action & Fast Gaining Stock Reports - Newser
Momentum divergence signals in Recursion Pharmaceuticals Inc. chartRecession Risk & Weekly High Potential Stock Alerts - Newser
Why Recursion Pharmaceuticals Stock Caught a Cold This Week - Nasdaq
Bollinger Bands Show Potential Breakout in Recursion Pharmaceuticals Inc.2025 Macro Impact & Risk Adjusted Swing Trade Ideas - 더경남뉴스
Recursion Pharmaceuticals (RXRX) Sees Sales And Revenue Growth In Q2 2025 - Yahoo Finance
Recursion Pharmaceuticals' Share Price Decline: A Biotech Innovation Crossroads for Long-Term Investors - AInvest
Recursion Pharmaceuticals Inc.’s Beta Climbs After Market VolatilityMarket Performance Report & Free Weekly Chart Analysis and Trade Guides - classian.co.kr
0.98%
8.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):